ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC (JAZZ)

123.45
1.81
(1.49%)
Closed December 04 4:00PM
122.50
-0.95
( -0.77% )
Pre Market: 7:36AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
122.50
Bid
121.00
Ask
127.00
Volume
770
0.00 Day's Range 0.00
99.06 52 Week Range 134.17
Market Cap
Previous Close
123.45
Open
-
Last Trade
60
@
123.6
Last Trade Time
08:00:00
Financial Volume
-
VWAP
-
Average Volume (3m)
620,811
Shares Outstanding
60,454,592
Dividend Yield
-
PE Ratio
17.99
Earnings Per Share (EPS)
6.86
Revenue
3.83B
Net Profit
414.83M

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of met... Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dublin, Irl
Founded
-
Jazz Pharmaceuticals PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker JAZZ. The last closing price for Jazz Pharmaceuticals was $123.45. Over the last year, Jazz Pharmaceuticals shares have traded in a share price range of $ 99.06 to $ 134.17.

Jazz Pharmaceuticals currently has 60,454,592 shares outstanding. The market capitalization of Jazz Pharmaceuticals is $7.46 billion. Jazz Pharmaceuticals has a price to earnings ratio (PE ratio) of 17.99.

JAZZ Latest News

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii...

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024 PR Newswire DUBLIN, Dec. 4, 2024 DUBLIN, Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc...

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting PR Newswire DUBLIN...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary...

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference PR Newswire DUBLIN, Nov. 19, 2024 DUBLIN, Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.39-0.317356985922122.89123.57120.5101427926122.13238539CS
45.54.70085470085117128.99115.65710990123.22703984CS
1216.6915.7735563746105.81128.99104.62620811115.38843229CS
2615.6414.6359723002106.86128.9999.06671742111.97586659CS
521.591.31502770656120.91134.1799.06666817114.36103991CS
1561.441.18949281348121.06169.9899.06596905131.4498516CS
260-27.34-18.2461292045149.8418986.88618855135.84073118CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PRFXPainReform Ltd
$ 6.30
(135.07%)
14.61M
BJDXBluejay Diagnostics Inc
$ 6.97
(79.18%)
9.48M
SVMHSRIVARU Holding Ltd
$ 0.0357
(51.91%)
211.32M
TARAProtara Therapeutics Inc
$ 5.23
(47.74%)
9.67M
PBMPsyence Biomedical Ltd
$ 3.58
(42.06%)
12.86M
BLUEbluebird bio Inc
$ 0.5199
(-29.39%)
1.22M
CYCNCyclerion Therapeutics Inc
$ 4.65
(-26.77%)
220.07k
STECSantech Holdings Limited
$ 0.735
(-24.23%)
3.85M
NCNOnCino Inc
$ 33.91
(-20.21%)
68.72k
SRMSRM Entertainment Inc
$ 0.9285
(-19.96%)
890.5k
SVMHSRIVARU Holding Ltd
$ 0.0354
(50.64%)
211.58M
PRFXPainReform Ltd
$ 6.30
(135.07%)
14.61M
PBMPsyence Biomedical Ltd
$ 3.58
(42.06%)
12.86M
TARAProtara Therapeutics Inc
$ 5.25
(48.31%)
9.69M
BJDXBluejay Diagnostics Inc
$ 6.98
(79.43%)
9.48M

JAZZ Discussion

View Posts
Paullee Paullee 3 years ago
yes, their major source of income is about to have major competition
👍️0
megatron31 megatron31 3 years ago
Any reasons why this has sold off so aggressively in the past 3 months? Other than “more sellers than buyers”

JAZZ
👍️0
ED25 ED25 4 years ago
JAZZ $$$$
👍️0
Chuxster Chuxster 4 years ago
Just watching on "60 Minutes" about Fluvoximine Maleate pills used on people who got Covid. Those who took this pills recovered without going to the hospital. Interesting considering the pills was for Obsessive Compulsive Disorder.
👍️0
whytestocks whytestocks 4 years ago
BREAKING NEWS: $JAZZ Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia

Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia Clinically meaningful and highly statistically significant results for pr...

In case you are interested JAZZ - Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia
👍️0
lucmariepierre lucmariepierre 5 years ago
They need Coca Cola cake industry for air industry and you like Coca Cola cake industry
👍️0
lucmariepierre lucmariepierre 5 years ago
I think blueberries are the best treatment for head diseases and associated with L-tyrosin from germany
👍️0
whytestocks whytestocks 6 years ago
News: $JAZZ Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019

DUBLIN , May 9, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial will be presented at the 33 rd Annual Meeting of the Associated Professional Sleep S...

Got this from https://marketwirenews.com/news-releases/jazz-pharmaceuticals-data-to-showcase-ongoing-sleep-medicine-research-at-sleep-2019-8151268.html
👍️0
lucmariepierre lucmariepierre 6 years ago
Did you try astragale Japanese tea and pissenlit instead
👍️0
lucmariepierre lucmariepierre 8 years ago
Did you try or try
Marjolaine and mélisse for the night to regulate his portfolio also :--/()
To feel better and optimistic as an habit
👍️0
xfrozenx xfrozenx 8 years ago
Owc$ following same path can't believe jazz use to be .90 7 years ago insane!!!!
👍️0
queenofjill queenofjill 8 years ago
Jazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017
👍️0
HiddenGem69 HiddenGem69 8 years ago
Nice low floater here. Biotech is coming back here
👍️0
lucmariepierre lucmariepierre 8 years ago
I think jazz products aren't as good as they are with a lot of suicides
👍️0
955 955 8 years ago
JAZZ always has delayed response to such news. Patience required here.




Why the stock is in dépressive mood
I thought the target could be 220 dollars with such pipeline




👍️0
lucmariepierre lucmariepierre 8 years ago
Why the stock is in dépressive mood
I thought the target could be 220 dollars with such pipeline
👍️0
europtiger europtiger 8 years ago
Nice!
👍️0
TREND1 TREND1 9 years ago
JAZZ D

👍️0
tpizzazz24 tpizzazz24 10 years ago
Looking back on JAZZ board. Trying to figure out who the biggest moron was. You're in the top 3 so far.
👍️0
Lotto123 Lotto123 10 years ago
Support level hit today...let's see if it holds....wouldn't mind seeing it driven a little lower, too smooth means boring & unplayable for any worthy profit....
👍️0
Lotto123 Lotto123 10 years ago
Back to playing JAZZ on small swings.... rock solid though...as far a solid rocks go..
👍️0
Lotto123 Lotto123 10 years ago
Got spoiled riding this puppy from the celler....topped out.....zzzzzzz,
👍️0
Lotto123 Lotto123 10 years ago
Love that pop in Jan....need a rumor of a stock split or sumtin'...
👍️0
UserAlias1 UserAlias1 10 years ago
*DJ Jazz Pharmaceuticals: Phase 1 Clinical Data Generated To Date Supports Completing The Phase 1 Evaluation Of Jzp-386 At The Originally Planned Highest Dose

Last update: 09/12/2014 8:31:26 am



(MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)

December 09, 2014 08:31 ET (13:31 GMT)

Copyright (c) 2014 Dow Jones & Company, Inc.

Jazz Pharma, Concert Pharma Report JZP-386 Program Update

Last update: 09/12/2014 8:30:50 am
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc.
(NASDAQ: CNCE) today announced that Phase 1 clinical data generated to date
supports completing the Phase 1 evaluation of JZP-386 at the originally
planned highest dose, which was not administered in the first Phase 1 trial
due to a technical dosing issue. The existing Phase 1 clinical data was
generated in a first-in-human trial evaluating the safety, pharmacokinetics,
and pharmacodynamics of JZP-386; enrollment was completed in the third
quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned
highest dose is expected to be initiated in the first quarter of 2015, with
data expected in the second quarter of 2015.

JZP-386 is a deuterium-containing analog of sodium oxybate. The Phase 1
program is comparing JZP-386 to sodium oxybate versus placebo in healthy
volunteers. The companies expect that the results from the upcoming Phase 1
trial will inform the next steps in the development program for JZP-386.

Sodium oxybate is the active ingredient in Xyrem, a prescription medicine
marketed in the United States by Jazz Pharmaceuticals to treat cataplexy and
excessive daytime sleepiness in patients with narcolepsy, a serious
neurological disorder that affects approximately 1 in 2000 people in the
United States.


Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Last update: 09/12/2014 8:30:00 am

DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)--December 09, 2014--

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that Phase 1 clinical data generated to date supports completing the Phase 1 evaluation of JZP-386 at the originally planned highest dose, which was not administered in the first Phase 1 trial due to a technical dosing issue. The existing Phase 1 clinical data was generated in a first-in-human trial evaluating the safety, pharmacokinetics, and pharmacodynamics of JZP-386; enrollment was completed in the third quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned highest dose is expected to be initiated in the first quarter of 2015, with data expected in the second quarter of 2015.

JZP-386 is a deuterium-containing analog of sodium oxybate. The Phase 1 program is comparing JZP-386 to sodium oxybate versus placebo in healthy volunteers. The companies expect that the results from the upcoming Phase 1 trial will inform the next steps in the development program for JZP-386.

Sodium oxybate is the active ingredient in Xyrem(R), a prescription medicine marketed in the United States by Jazz Pharmaceuticals to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, a serious neurological disorder that affects approximately 1 in 2000 people in the United States.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem(R) (sodium oxybate) oral solution, Erwinaze(R) (asparaginase Erwinia chrysanthemi), Prialt(R) (ziconotide) intrathecal infusion, Versacloz(R) (clozapine) oral suspension, FazaClo(R) (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the United States, including Erwinase(R) and Defitelio(R) (defibrotide). For more information, please visit www.jazzpharmaceuticals.com.

About Concert Pharmaceuticals

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform(R) (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The Company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer. For more information, please visit www.concertpharma.com.

About Xyrem

Xyrem(R) (sodium oxybate) oral solution, CIII, is indicated for the treatment of cataplexy in narcolepsy and for the treatment of EDS in narcolepsy. Xyrem may only be dispensed to patients enrolled in the Xyrem Success Program(R). Xyrem was first approved in the United States in 2002. Safety and effectiveness in pediatric patients have not been established.


IMPORTANT SAFETY INFORMATION
------------------------------------------------------------------------------
XYREM is a Central Nervous System (CNS) depressant. In clinical trials at
recommended doses, obtundation and clinically significant respiratory
depression occurred in XYREM-treated patients. Almost all of the patients who
received XYREM during clinical trials in narcolepsy were receiving CNS
stimulants. XYREM is the sodium salt of gamma hydroxybutyrate (GHB). Abuse of
GHB, either alone or in combination with other CNS depressants, is associated
with CNS adverse reactions, including seizure, respiratory depression,
decreases in the level of consciousness, coma, and death. Because of the risks
of CNS depression, abuse, and misuse, XYREM is available only through a
restricted distribution program called the XYREM Success Program(R), using a
centralized pharmacy. Prescribers and patients must enroll in the program. For
further information go to www.XYREM.com or call 1-866-XYREM88(R)
(1-866-997-3688).



Xyrem is contraindicated in combination with sedative hypnotics or alcohol and in patients with succinic semialdehyde dehydrogenase deficiency. Use caution when considering the concurrent use of Xyrem with other CNS depressants. Healthcare providers should caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that Xyrem does not affect them adversely. Xyrem is a Schedule III controlled substance. The rapid onset of sedation, coupled with the amnestic features of Xyrem, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g. assault victim). Monitor patients for emergent or increased depression and suicidality and for impaired motor/cognitive function. Episodes of sleepwalking should be fully evaluated and appropriate interventions considered. Consider the amount of daily sodium intake in each dose of Xyrem in patients sensitive to salt intake.

Jazz Pharmaceuticals plc "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to future events in the Phase 1 clinical program for JZP-386, the timing of the second Phase 1 clinical trial, the therapeutic potential of JZP-386 and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the timing and conduct of clinical trials and the therapeutic value of JZP-386; the uncertainty of regulatory approval; and those risks with respect to research and development and clinical trials detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, and future filings and reports by Jazz Pharmaceuticals. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

Concert Pharmaceuticals Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the future clinical development of JZP-386, the potential effectiveness of JZP-386, our plans and timelines for the clinical development of JZP-386 and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals and other factors discussed in the " Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

Jazz Pharmaceuticals and the Jazz Pharmaceuticals logo are registered trademarks of Jazz Pharmaceuticals plc or its subsidiaries.

Photos/Multimedia Gallery Available: www.businesswire.com/multimedia/home/20141209005304/en/

CONTACT: Jazz Pharmaceuticals plc

(investors)

Katherine Littrell, PhD, RN, U.S. + 650-496-2717

Ireland + 353 1 634 7887

investorinfo@jazzpharma.com

or

(media)

Laurie Hurley, U.S. + 1-650-496-2796

Ireland + 353 1 634 7894

or

Concert Pharmaceuticals

(investors)

Justine Koenigsberg, U.S. + 781-674-5284

ir@concertpharma.com

or

(media)

The Yates Network

Kathryn Morris, U.S. + 845-635-9828

SOURCE: Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc.
Copyright Business Wire 2014


(END) Dow Jones Newswires

December 09, 2014 08:30 ET (13:30 GMT)
👍️0
UserAlias1 UserAlias1 10 years ago
$JAZZ NEWS: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Last update: 09/12/2014 8:30:00 am

DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)--December 09, 2014--

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that Phase 1 clinical data generated to date supports completing the Phase 1 evaluation of JZP-386 at the originally planned highest dose, which was not administered in the first Phase 1 trial due to a technical dosing issue. The existing Phase 1 clinical data was generated in a first-in-human trial evaluating the safety, pharmacokinetics, and pharmacodynamics of JZP-386; enrollment was completed in the third quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned highest dose is expected to be initiated in the first quarter of 2015, with data expected in the second quarter of 2015.

JZP-386 is a deuterium-containing analog of sodium oxybate. The Phase 1 program is comparing JZP-386 to sodium oxybate versus placebo in healthy volunteers. The companies expect that the results from the upcoming Phase 1 trial will inform the next steps in the development program for JZP-386.

Sodium oxybate is the active ingredient in Xyrem(R), a prescription medicine marketed in the United States by Jazz Pharmaceuticals to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, a serious neurological disorder that affects approximately 1 in 2000 people in the United States.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem(R) (sodium oxybate) oral solution, Erwinaze(R) (asparaginase Erwinia chrysanthemi), Prialt(R) (ziconotide) intrathecal infusion, Versacloz(R) (clozapine) oral suspension, FazaClo(R) (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the United States, including Erwinase(R) and Defitelio(R) (defibrotide). For more information, please visit www.jazzpharmaceuticals.com.

About Concert Pharmaceuticals

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform(R) (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The Company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer. For more information, please visit www.concertpharma.com.

About Xyrem

Xyrem(R) (sodium oxybate) oral solution, CIII, is indicated for the treatment of cataplexy in narcolepsy and for the treatment of EDS in narcolepsy. Xyrem may only be dispensed to patients enrolled in the Xyrem Success Program(R). Xyrem was first approved in the United States in 2002. Safety and effectiveness in pediatric patients have not been established.


IMPORTANT SAFETY INFORMATION
------------------------------------------------------------------------------
XYREM is a Central Nervous System (CNS) depressant. In clinical trials at
recommended doses, obtundation and clinically significant respiratory
depression occurred in XYREM-treated patients. Almost all of the patients who
received XYREM during clinical trials in narcolepsy were receiving CNS
stimulants. XYREM is the sodium salt of gamma hydroxybutyrate (GHB). Abuse of
GHB, either alone or in combination with other CNS depressants, is associated
with CNS adverse reactions, including seizure, respiratory depression,
decreases in the level of consciousness, coma, and death. Because of the risks
of CNS depression, abuse, and misuse, XYREM is available only through a
restricted distribution program called the XYREM Success Program(R), using a
centralized pharmacy. Prescribers and patients must enroll in the program. For
further information go to www.XYREM.com or call 1-866-XYREM88(R)
(1-866-997-3688).



Xyrem is contraindicated in combination with sedative hypnotics or alcohol and in patients with succinic semialdehyde dehydrogenase deficiency. Use caution when considering the concurrent use of Xyrem with other CNS depressants. Healthcare providers should caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that Xyrem does not affect them adversely. Xyrem is a Schedule III controlled substance. The rapid onset of sedation, coupled with the amnestic features of Xyrem, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g. assault victim). Monitor patients for emergent or increased depression and suicidality and for impaired motor/cognitive function. Episodes of sleepwalking should be fully evaluated and appropriate interventions considered. Consider the amount of daily sodium intake in each dose of Xyrem in patients sensitive to salt intake.

Jazz Pharmaceuticals plc "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to future events in the Phase 1 clinical program for JZP-386, the timing of the second Phase 1 clinical trial, the therapeutic potential of JZP-386 and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the timing and conduct of clinical trials and the therapeutic value of JZP-386; the uncertainty of regulatory approval; and those risks with respect to research and development and clinical trials detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, and future filings and reports by Jazz Pharmaceuticals. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

Concert Pharmaceuticals Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the future clinical development of JZP-386, the potential effectiveness of JZP-386, our plans and timelines for the clinical development of JZP-386 and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals and other factors discussed in the " Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

Jazz Pharmaceuticals and the Jazz Pharmaceuticals logo are registered trademarks of Jazz Pharmaceuticals plc or its subsidiaries.

Photos/Multimedia Gallery Available: www.businesswire.com/multimedia/home/20141209005304/en/

CONTACT: Jazz Pharmaceuticals plc

(investors)

Katherine Littrell, PhD, RN, U.S. + 650-496-2717

Ireland + 353 1 634 7887

investorinfo@jazzpharma.com

or

(media)

Laurie Hurley, U.S. + 1-650-496-2796

Ireland + 353 1 634 7894

or

Concert Pharmaceuticals

(investors)

Justine Koenigsberg, U.S. + 781-674-5284

ir@concertpharma.com

or

(media)

The Yates Network

Kathryn Morris, U.S. + 845-635-9828

SOURCE: Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc.
Copyright Business Wire 2014


(END) Dow Jones Newswires

December 09, 2014 08:30 ET (13:30 GMT)
👍️0
maytepper maytepper 10 years ago
$JAZZ Cantor Raises Jazz Pharmaceuticals Price Target On Xyrem Scenario Analysis http://www.smarteranalyst.com/2014/11/03/cantor-raises-jazz-pharmaceuticals-price-target-on-xyrem-scenario-analysis/
👍️0
Setay Setay 10 years ago
I am told JAZZ is turned out to be an incredible Bio Tech Investment for those with Vision:
👍️0
jazz_1 jazz_1 10 years ago
For some reason I am very partial to this particular stock! :)

-Jazz
👍️0
maytepper maytepper 10 years ago
$JAZZ $FLML Canaccord Provides Input Into Jazz’s Patent Fight Against Flamel On Xyrem http://www.smarteranalyst.com/2014/10/03/canaccord-provides-input-jazzs-patent-fight-flamel-xyrem/
👍️0
Skitradr Skitradr 10 years ago
Loved it entered with entered fri the $165.00 sept 20 calls for $2.41......exited Monday @ $8.00.....
👍️0
Skitradr Skitradr 10 years ago
Got out of this Monday when she hit 171...
👍️0
Lotto123 Lotto123 10 years ago
lolzzz, I really did use it a lot too....great system....
Yes, JAZZ has been very good to me....Been in and out since it was on the $1 menu back in '09 when I signed up on IHUB.
Kept reloading on dips when I would trip out...

Wish I would have put 20k into it instead of 5k but it was a longshot back then...shouldof, couldof, wouldof....lolzzzzzz

Have a great weekend Skitradr...

Marked ya....I had GE too back then...Got it when OBama got in office...Illinois connection there...knew that would pay off ok...lol....
👍️0
Skitradr Skitradr 10 years ago
That's funny.......just found one of you're old post from way back in feb 2011....... Talking about the cup and saucer......wow....looks like you have had an incredible ride...

Great job.....hope she keeps going for you..
👍️0
Lotto123 Lotto123 10 years ago
Buy point at $165+....nice..... dammmm, I haven't done a line look at for a while....have found some nice gainers off the old cup and saucer....nice reminder too....lol...
👍️0
Skitradr Skitradr 10 years ago
This sure doesn't hurt the cause .......




Big money will start coming in now that it the IBD buy point......

Should be a fun couple of weeks......

GL
👍️0
Lotto123 Lotto123 10 years ago
Nice ......this one's been very nice to me over the years ...

JAZZ has been ripe for a buyout for quite a while.... never know...
👍️0
Skitradr Skitradr 10 years ago
I agree.....picked up some sept 20th $ 165.00 calls @ $ 3.11 this morning.......news should hit this weekend about possible buy out .....hoping for nice gap up Monday .....

GL
👍️0
Lotto123 Lotto123 10 years ago
JAZZ Nice day....weeeeeeeeeeeeeeeeeeeee...
👍️0
Lotto123 Lotto123 10 years ago
You still holding this treasure?
👍️0
Lotto123 Lotto123 10 years ago
Double top or breakout coming...
👍️0
Lotto123 Lotto123 10 years ago
JAZZ crankin' again... weeeeeeeeeeeeee...
👍️0
Lotto123 Lotto123 10 years ago
JAZZ - My personal gift from God...

No, a .12pps turd isn't Jazz....lol...
👍️0
maytepper maytepper 10 years ago
Cantor Fitzgerald Reiterates Hold On Jazz Pharmaceuticals Following 2Q14 Results http://www.smarteranalyst.com/2014/08/08/cantor-fitzgerald-reiterates-hold-on-jazz-pharmaceuticals-following-2q14-results/
👍️0
expediter13 expediter13 10 years ago
AMBS is a Sham... Look at the BS leadership, the dilution, etc. Completely different type of biotech. One is real, the other is not... Been in and out of jazz for years and wish I had just stayed...
👍️0
Lotto123 Lotto123 10 years ago
Ripe for inversion....cheap price considering...
👍️0
Lotto123 Lotto123 10 years ago
WSJ: http://blogs.wsj.com/pharmalot/2014/06/20/a-look-at-the-european-pharmaceutical-singletons/
👍️0
Lotto123 Lotto123 10 years ago
Triggered out on dip...Loading back up first sign..
👍️0
Lotto123 Lotto123 10 years ago
LOLZZZZZZ....Not sure who is still around....I loaded up as a lotto play in '09 as you could buy all you wanted for under a dolla ... I let the load ride up to the drop off after mid $170's as it hit a stop trigger I had set. Truly just a friggin' monsta lotto as nothing stopped it....Any short action was quickly taken out. The smart ones just stayed away after the initial burning of their postions....lol...

First low resistance was low $120's so I put a portion of the BankLoad back in on the second dip in May and will ride this as I am playing just technicals on this now since I have no time for DD on it but haven't heard anything negatives. Could be hitting it's top....A forward split would be a nice reward for the longs though and that would get it moving again I would bet, ....
RSI still has a ton of head room after the cool off and MFI looks like more is flowing into this beast....Could see $200 before it hits the high water mark again....

Ya never retire from da game

Found it while I was playing GNTA (Genta) as that was channeling nicely for over a year...nice ATM there back then...lol....

I have 2 little ones so I let my IHub script run out last year and am just trying to get back into swing here again....A sell trigger going off on Jazz will do that to one...


Just checked out the board after I ran across this old post of mine....I have to be premium again to do searches, even on my own posts....lol...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59793209

My Tax Accountant better be worth his weight in gold this year...lolzzzzzzzzzzzzzz.... Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeee.....



Have a good one!



👍️0
longboardsurfer90210 longboardsurfer90210 11 years ago
Just curious. I am from another board (almost embarrassed to mention due to the clowns that post nonsense constantly, ie AMBS) as was wondering if there were any here who had rode this thing all the way up? Are those people still posting, or have they long since retired and have distanced themselves from the market? Just curious who would be left posting here on this board after such a huge run.
👍️0
JojoK JojoK 11 years ago
lol, funny to read old comments like this
👍️0

Your Recent History

Delayed Upgrade Clock